Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

KZR vs COCP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

KZR Captures Overall Composite Edge (60.1 BUY vs 47.1 HOLD), While COCP Leads 3–2 on Growth & Valuation Pillars

KZR Overall Winner 6-Pillar Tally: KZR 2 – 3 COCP (1 Tie) Matrix Metrics: KZR 6 – 1 COCP

As of Nov 16, 2026, Kezar Life Sciences, Inc. (KZR) captures the overall head-to-head institutional edge over Cocrystal Pharma, Inc. (COCP) on higher Unified Composite conviction (60.1/100 BUY vs. 47.1/100 HOLD) after splitting the core matrix 6–1 (led by Profitability & Quality, Options & Positioning), while COCP wins 3–2 across the 6-pillar growth and valuation breakdown. KZR trades at $7.29 (N/M Forward P/E, 0.0% operating margin) versus COCP at $1.00 (N/M Forward P/E, -3063.6% operating margin).

  • Growth vs. Quality Trade-Off: KZR earns the overall head-to-head edge with a stronger Unified Composite Score (60.1/100 BUY vs. COCP 47.1/100 HOLD) and 0.60β · 8% Vol risk profile, whereas COCP leads top-line expansion (+26.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About KZR vs COCP
KZR NASDAQ Head-to-Head Winner
Kezar Life Sciences, Inc. Common Stock
Pharmaceutical Preparations
$7.29
-0.95% 1D
Market Cap $54.4M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.60β · 8% Vol
Unified Composite Score
60.1 / 100 BUY
Tech 40.0 Fund 51.0 Flow 56.0 Mom 58.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.7% over 20 days), RSI 53
RSI-14: 52.6 · SMA20: $7.33 · SMA50: $7.12
COCP NASDAQ
Cocrystal Pharma, Inc. Common Stock
Pharmaceutical Preparations
$1.00
+1.98% 1D
Market Cap $19.6M
TTM Revenue $330,000
Forward P/E N/M
Beta / 30D Vol 1.04β · 54% Vol
Unified Composite Score
47.1 / 100 HOLD
Tech 51.0 Fund 48.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.3 · SMA20: $1.00 · SMA50: $1.08

6-Pillar Scorecard Institutional Category Breakdown (KZR 2 – 3 COCP)

Columns: Metric · KZR · COCP
1. Valuation Multiples COCP
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 49.7x
2. Growth & Scale COCP
Revenue Growth (YoY) +0.0% +26.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $330,000
Market Cap $54.4M $19.6M
3. Profitability & Quality KZR
Gross Margin N/A N/A
Operating Margin 0.0% -3063.6%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -59.9% -311.7%
4. Balance Sheet & Cash Flow COCP
Cash Generation (TTM) N/A -$7.6M
Cash Flow Margin N/A N/A
Net Cash / Leverage $9.56 Book/Sh · -59.9% ROE $3.3M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning KZR
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 37.2% (9th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: KZR (6) vs COCP (1)
Institutional Metric KZR COCP Criterion Row Edge
Market Capitalization
Scale
$54.4M $19.6M Larger Scale KZR
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +26.9% Higher Growth COCP
Operating Margin (TTM)
Profitability
0.0% -3063.6% Higher Margin KZR
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-59.9% -311.7% Higher ROE KZR
52-Week Range Position
Momentum
94% ($4–$8) 19% ($1–$2) Stronger Trend KZR
Beta / 30D Volatility
Risk Regime
0.60β · 8% Vol 1.04β · 54% Vol Lower Realized Risk KZR
Unified Institutional Score
Composite Signal
60.1 / 100 (BUY) 47.1 / 100 (HOLD) Higher Composite KZR
Trailing 12M Revenue (USD)
Operating Scale
N/A $330,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 49.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($9.56 Book/Sh · -59.9% ROE) -$7.6M ($3.3M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon COCP +1.52 pp
KZR: -0.82% · COCP: +0.7%
3M Horizon COCP +29.35 pp
KZR: +19.12% · COCP: +48.47%
6M Horizon COCP +21.27 pp
KZR: +18.54% · COCP: +39.81%
1Y Horizon COCP +21.27 pp
KZR: +18.54% · COCP: +39.81%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on KZR vs COCP. Trailing 12-month operating profitability (KZR 0.0% vs COCP -3063.6%) and valuation multiples (KZR N/M vs COCP N/M Forward P/E) are benchmarked directly in Pillar 4 below.

KZR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-59.9% · N/M
COCP ADR TTM Benchmark FX-Normalized USD
TTM Revenue$330,000
Gross MarginN/A
Op. Margin-3063.6%
ROE / Fwd P/E-311.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
KZR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 37.2%
IV Percentile 9th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact KZR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
COCP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact COCP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
KZR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $54.4M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
COCP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $19.6M market capitalization and -3063.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ KZR vs COCP Key Questions & Quantitative Answers

As of Nov 16, 2026, Kezar Life Sciences, Inc. (KZR) captures the overall head-to-head institutional edge over Cocrystal Pharma, Inc. (COCP) on higher Unified Composite conviction (60.1/100 BUY vs. 47.1/100 HOLD) after splitting the core matrix 6–1 (led by Profitability & Quality, Options & Positioning), while COCP wins 3–2 across the 6-pillar growth and valuation breakdown. KZR trades at $7.29 (N/M Forward P/E, 0.0% operating margin) versus COCP at $1.00 (N/M Forward P/E, -3063.6% operating margin). Growth vs. Quality Trade-Off: KZR earns the overall head-to-head edge with a stronger Unified Composite Score (60.1/100 BUY vs. COCP 47.1/100 HOLD) and 0.60β · 8% Vol risk profile, whereas COCP leads top-line expansion (+26.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.

COCP leads the Growth & Scale pillar: KZR posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with COCP at +26.9% YoY revenue growth and +0.0% YoY earnings growth on $330,000 TTM revenue (N/A gross margin, -3063.6% operating margin). On trailing 12-month operating scale, KZR generates N/A in USD-normalized revenue versus $330,000 for COCP. In operating R&D and SG&A reinvestment, KZR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for COCP.

COCP screens cheaper on headline valuation multiples. KZR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas COCP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 49.7x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against KZR (-59.9% ROE) versus COCP (-311.7% ROE) capital efficiency.

In options market volatility and institutional positioning, KZR carries 37.2% implied volatility (9th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.60β · 8% Vol realized risk). By comparison, COCP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.04β · 54% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.